| Sex-dependent interactions between prodromal intestinal inflammation and LRRK2 G2019S in mice promote endophenotypes of Parkinson's disease. | Sex-dependent interactions between prodromal intestinal inflammation and LRRK2 G2019S in mice promote endophenotypes of Parkinson's disease.
Fang P, Yu LW, Espey H, Agirman G, Kazmi SA, Li K, Deng Y, Lee J, Hrncir H, Romero-Lopez A, Arnold AP, Hsiao EY., Free PMC Article | 08/8/2024 |
| The Evolution of Genetic Variability at the LRRK2 Locus. | The Evolution of Genetic Variability at the LRRK2 Locus.
Guenther DT, Follett J, Amouri R, Sassi SB, Hentati F, Farrer MJ., Free PMC Article | 07/31/2024 |
| Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant. | Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.
Kmiecik MJ, Micheletti S, Coker D, Heilbron K, Shi J, Stagaman K, Filshtein Sonmez T, Fontanillas P, Shringarpure S, Wetzel M, Rowbotham HM, Cannon P, Shelton JF, Hinds DA, Tung JY, 23andMe Research Team, Holmes MV, Aslibekyan S, Norcliffe-Kaufmann L., Free PMC Article | 06/11/2024 |
| Multi-tracer PET correlation analysis reveals disease-specific patterns in Parkinson's disease and asymptomatic LRRK2 pathogenic variant carriers compared to healthy controls. | Multi-tracer PET correlation analysis reveals disease-specific patterns in Parkinson's disease and asymptomatic LRRK2 pathogenic variant carriers compared to healthy controls.
Mannheim JG, Fu JF, Wegener T, Klyuzhin IS, Vafai N, Shahinfard E, McKenzie J, Strongosky A, Wszolek ZK, Jon Stoessl A, Sossi V., Free PMC Article | 06/11/2024 |
| Targeting Rab-RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's disease. | Targeting Rab-RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's disease.
Alexander KK, Naaldijk Y, Fasiczka R, Brahmia B, Chen T, Hilfiker S, Kennedy EJ. | 04/10/2024 |
| RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors. | RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors.
Dou D, Aiken J, Holzbaur ELF., Free PMC Article | 03/22/2024 |
| Endogenous Rab38 regulates LRRK2's membrane recruitment and substrate Rab phosphorylation in melanocytes. | Endogenous Rab38 regulates LRRK2's membrane recruitment and substrate Rab phosphorylation in melanocytes.
Unapanta A, Shavarebi F, Porath J, Shen Y, Balen C, Nguyen A, Tseng J, Leong WS, Liu M, Lis P, Di Pietro SM, Hiniker A., Free PMC Article | 03/4/2024 |
| The Effect of p.G2019S Mutation in the LRRK2 Gene on the Activity of Lysosomal Hydrolases and the Clinical Features of Parkinson's Disease Associated with p.N370S Mutation in the GBA1 Gene. | The Effect of p.G2019S Mutation in the LRRK2 Gene on the Activity of Lysosomal Hydrolases and the Clinical Features of Parkinson's Disease Associated with p.N370S Mutation in the GBA1 Gene.
Usenko TS, Timofeeva A, Beletskaia M, Basharova K, Baydakova G, Bezrukova A, Grunina M, Emelyanov A, Miliukhina I, Zakharova E, Pchelina S. | 03/1/2024 |
| The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons. | The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons.
Mamais A, Sanyal A, Fajfer A, Zykoski CG, Guldin M, Riley-DiPaolo A, Subrahmanian N, Gibbs W, Lin S, LaVoie MJ., Free PMC Article | 02/21/2024 |
| VPS35 and retromer dysfunction in Parkinson's disease. | VPS35 and retromer dysfunction in Parkinson's disease.
Rowlands J, Moore DJ., Free PMC Article | 02/21/2024 |
| A Complex Interplay of DJ-1, LRRK2, and Nrf2 in the Regulation of Mitochondrial Function in Cypermethrin-Induced Parkinsonism. | A Complex Interplay of DJ-1, LRRK2, and Nrf2 in the Regulation of Mitochondrial Function in Cypermethrin-Induced Parkinsonism.
Sarkar A, Singh MP. | 02/15/2024 |
| Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study. | Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study.
Sun X, Dou K, Xue L, Xie Y, Yang Y, Xie A., Free PMC Article | 02/5/2024 |
| The V-ATPase-ATG16L1 axis recruits LRRK2 to facilitate the lysosomal stress response. | The V-ATPase-ATG16L1 axis recruits LRRK2 to facilitate the lysosomal stress response.
Eguchi T, Sakurai M, Wang Y, Saito C, Yoshii G, Wileman T, Mizushima N, Kuwahara T, Iwatsubo T., Free PMC Article | 01/17/2024 |
| Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes. | Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.
Wang X, Bondar VV, Davis OB, Maloney MT, Agam M, Chin MY, Cheuk-Nga Ho A, Ghosh R, Leto DE, Joy D, Calvert MEK, Lewcock JW, Di Paolo G, Thorne RG, Sweeney ZK, Henry AG., Free PMC Article | 01/3/2024 |
| LINC00707 promotes multidrug resistance of ovarian cancer cells by targeting the miR-382-5p/LRRK2 axis. | LINC00707 promotes multidrug resistance of ovarian cancer cells by targeting the miR-382-5p/LRRK2 axis.
Zhao MW, Lin CJ, Qiu JP. | 12/27/2023 |
| Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function. | Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function.
Ohtonen S, Giudice L, Jäntti H, Fazaludeen MF, Shakirzyanova A, Gómez-Budia M, Välimäki NN, Niskanen J, Korvenlaita N, Fagerlund I, Koistinaho J, Amiry-Moghaddam M, Savchenko E, Roybon L, Lehtonen Š, Korhonen P, Malm T., Free PMC Article | 12/20/2023 |
| The Parkinson's disease-associated mutation LRRK2 G2385R alters mitochondrial biogenesis via the PGC-1alpha-TFAM pathway. | The Parkinson's disease-associated mutation LRRK2 G2385R alters mitochondrial biogenesis via the PGC-1α-TFAM pathway.
Xue J, Zhang J, Zhang J, Liu J, Wang F, Li K, Liu C. | 12/6/2023 |
| Role of the Residue Q1919 in Increasing Kinase Activity of G2019S LRRK2 Kinase: A Computational Study. | Role of the Residue Q1919 in Increasing Kinase Activity of G2019S LRRK2 Kinase: A Computational Study.
Naskar A, Bhanja KK, Roy RK, Patra N. | 11/6/2023 |
| LRRK2 is involved in the chemotaxis of neutrophils and differentiated HL-60 cells, and the inhibition of LRRK2 kinase activity increases fMLP-induced chemotactic activity. | LRRK2 is involved in the chemotaxis of neutrophils and differentiated HL-60 cells, and the inhibition of LRRK2 kinase activity increases fMLP-induced chemotactic activity.
Mazaki Y, Handa H, Fumoto Y, Horinouchi T, Onodera Y., Free PMC Article | 11/1/2023 |
| Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism. | Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
Lüth T, Gabbert C, Koch S, König IR, Caliebe A, Laabs BH, Hentati F, Sassi SB, Amouri R, Spielmann M, Klein C, Grünewald A, Farrer MJ, Trinh J. | 11/1/2023 |
| Localization of PPM1H phosphatase tunes Parkinson's disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis. | Localization of PPM1H phosphatase tunes Parkinson's disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis.
Yeshaw WM, Adhikari A, Chiang CY, Dhekne HS, Wawro PS, Pfeffer SR., Free PMC Article | 11/1/2023 |
| Differences in EEG Event-Related Potentials during Dual Task in Parkinson's Disease Carriers and Non-Carriers of the G2019S-LRRK2 Mutation. | Differences in EEG Event-Related Potentials during Dual Task in Parkinson's Disease Carriers and Non-Carriers of the G2019S-LRRK2 Mutation.
Shkury E, Danziger-Schragenheim S, Katzir Z, Ezra Y, Giladi N, Mirelman A, Maidan I., Free PMC Article | 10/25/2023 |
| The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson's Disease. | The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson's Disease.
Albus A, Kronimus Y, Burg-Roderfeld M, van der Wurp H, Willbold D, Ziehm T, Dodel R, Ross JA., Free PMC Article | 10/5/2023 |
| Leucine-rich repeat kinase 2 at a glance. | Leucine-rich repeat kinase 2 at a glance.
Zhu C, Herbst S, Lewis PA., Free PMC Article | 09/18/2023 |
| LRRK2 aggravates kidney injury through promoting MFN2 degradation and abnormal mitochondrial integrity. | LRRK2 aggravates kidney injury through promoting MFN2 degradation and abnormal mitochondrial integrity.
Zhang S, Qian S, Liu H, Xu D, Xia W, Duan H, Wang C, Yu S, Chen Y, Ji P, Wang S, Cui X, Wang Y, Shen H., Free PMC Article | 09/13/2023 |